Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN57325925
ISRCTN57325925
Completed
未知

Multicenter study to evaluate the clinical and cost-effectiveness of a youth culturally adapted therapy (YCMAP)

Pakistan Institute of Learning and Living0 sites684 target enrollmentFebruary 3, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSelf harmMental and Behavioural Disorders

Overview

Phase
未知
Intervention
Not specified
Conditions
Self harm
Sponsor
Pakistan Institute of Learning and Living
Enrollment
684
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35568489/ (added 09/04/2024)

Registry
who.int
Start Date
February 3, 2022
End Date
September 8, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Age 12\-18 years
  • •2\. Presenting to the participating GPs, emergency departments or admitted after an episode of self\-harm to the participating hospitals or self\-referrals
  • •3\. History of recent self\-harm, defined as self\-harm occurring within the last 3 months (from the initial identification of a potential participant)
  • •4\. Participants living within the catchment area of the participating practices and hospitals
  • •5\. Not needing inpatient psychiatric treatment

Exclusion Criteria

  • •1\. Severe mental illness (such as psychotic disorder) as self\-harm commonly co\-occurs with other mental health difficulties
  • •2\. Conditions limiting engagement with assessment or intervention, including developmental and communication disorders, intellectual disabilities and autistic spectrum disorders
  • •3\. Temporary resident unlikely to be available for follow up

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
TRABIO: registry for documenting treatment success after kidney transplant rejectionsKidney biopsies for suspected acute and chronic rejections in patients with kidney graftsUrological and Genital Diseases
ISRCTN78772632Chiesi (Germany)800
Completed
Phase 3
Vaccine Response On/off Methotrexate (VROOM): does temporarily suspending methotrexate treatment for two weeks enhance COVID-19 vaccine response?
ISRCTN11442263CTU0373383
Completed
Phase 3
Trial investigating the effectiveness of a medical device (Alpha-Stim AID) for the treatment of depressive symptoms for patients in primary care
ISRCTN11853110niversity of Nottingham236
Active, not recruiting
Not Applicable
Does screening with the Galleri test in the NHS reduce the likelihood of a late-stage cancer diagnosis?Multi cancer early detection in people without symptomsCancer
ISRCTN91431511GRAIL Bio UK Ltd.140,000
Active, not recruiting
Not Applicable
Autologous stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing-remitting multiple sclerosisRelapsing-remitting multiple sclerosisNervous System DiseasesMultiple sclerosis
ISRCTN88667898Sheffield Teaching Hospitals NHS Foundation Trust198